OQROSign up free
Insider trade

Regeneron Pharmaceuticals (REGN): Director sold ~$1.2M

Bonnie L Bassler, Director at Regeneron Pharmaceuticals, sold ~$1.2M of Regeneron Pharmaceuticals shares.

~$1.2M
Approx. value · 1,500 sh @ $800.00
1,703
Holds after · shares reported
Traded
Jan 7, 2026
Filed
Jan 8, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Nov 7, 2025InsiderOfficer sold ~$281K of REGN shares in the open market
  2. Nov 18, 2025CongressDisclosed purchase of REGN — reported range $1,001 - $15,000
  3. Nov 19, 2025FDAFDA drug approval: Eylea HD
  4. Nov 20, 2025InsiderDirector sold ~$570K of REGN shares in the open market
  5. Jan 7, 2026 · this disclosureInsiderDirector sold ~$1.2M of REGN shares in the open market

What came next

  1. Jan 12, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
  2. Jan 30, 2026Company filing · Form 8-K · ResultsReported its results
  3. Feb 9, 2026Insider · 2 peopleInsiders: 24 sales (~$1.7M)
  4. Feb 12, 2026CongressDisclosed purchase of REGN — reported range $1,001 - $15,000
  5. Feb 19, 2026Insider · 1 personInsiders: 11 sales (~$1.3M)
  6. Feb 23, 2026FDAFDA drug approval: Dupixent
  7. Mar 2, 2026Insider · 1 personInsiders: 13 sales (~$79K)
  8. Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  9. Apr 1, 2026Insider · 1 personInsiders: 9 sales (~$78K)
  10. Apr 2, 2026FDAFDA drug approval: Eylea HD
  11. Apr 8, 2026Company filing · Form 8-K · ResultsReported its results
  12. Apr 22, 2026FDAFDA drug approval: Dupixent
  13. Apr 29, 2026Company filing · Form 8-K · ResultsReported its results
  14. Apr 30, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.4%
  15. May 1, 2026Insider · 1 personInsiders: 12 sales (~$71K)
  16. May 6, 2026Government · Federal Register noticeIssuance of Priority Review Voucher; Rare Pediatric Disease Product; OTARMENI (lunsotogene parvec-cwha)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Regeneron Pharmaceuticals

For Regeneron Pharmaceuticals, OQRO holds 73 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its REGN page.

Other recent filings by Bonnie L Bassler, Director

The full history of Bonnie L Bassler, Director is on the profile page.

How this filing works

Explore the data

Other disclosures at Regeneron Pharmaceuticals

Everything OQRO holds on this company is on its REGN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Sign up freeAlready have an account? Log in

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data